Cargando…

A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

PURPOSE: A multi-site Phase I trial was conducted to determine the safety, maximum tolerated dose, and pharmacokinetics (PK) of Veliparib, a Poly (ADP-ribose) polymerase [PARP] enzyme inhibitor, when administered with temozolomide (TMZ) alone and then with temozolomide and radiation (RT) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleinberg, Lawrence, Ye, Xiaobu, Supko, Jeff, Stevens, Glenn H.J., Shu, Hui-Kuo, Mikkelsen, Tom, Lieberman, Frank, Lesser, Glenn, Lee, Emerson, Grossman, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635324/ https://www.ncbi.nlm.nih.gov/pubmed/37961385 http://dx.doi.org/10.21203/rs.3.rs-3466927/v1

Ejemplares similares

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
por: Rosenfeld, Myrna R, et al.
Publicado: (2014)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Using Light for Therapy of Glioblastoma Multiforme (GBM)
por: Vasilev, Alex, et al.
Publicado: (2020)

FAM72, Glioblastoma Multiforme (GBM) and Beyond
por: Ho, Nguyen Thi Thanh, et al.
Publicado: (2021)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
por: Alimohammadi, Ehsan, et al.
Publicado: (2020)

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
por: Yalamarty, Satya Siva Kishan, et al.
Publicado: (2023)

Migration-Associated Transportome and Therapeutic Potential in Glioblastoma Multiforme (GBM)
por: Vaid, Samir, et al.
Publicado: (2023)

Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines
por: Binder, Zev A., et al.
Publicado: (2016)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

A Randomized Study of Short Course (One Week) Radiation Therapy with or without Temozolomide in Elderly and/or Frail Patients with Newly Diagnosed Glioblastoma (GBM)
por: Thakur, Subhash, et al.
Publicado: (2022)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

Cluster and Principal Component Analysis of Human Glioblastoma Multiforme (GBM) Tumor Proteome
por: Pooladi, Mehdi, et al.
Publicado: (2014)

microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)—Recent Literature Review
por: Makowska, Marianna, et al.
Publicado: (2023)

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009)

Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
por: Toren, Amos, et al.
Publicado: (2016)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)
por: Thivat, Emilie, et al.
Publicado: (2023)

Ultrastructural characterization of primary cilia in pathologically characterized human glioblastoma multiforme (GBM) tumors
por: Moser, Joanna J, et al.
Publicado: (2014)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
por: Faustino, Alexandre Ciuffi, et al.
Publicado: (2020)

Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era
por: Internò, Valeria, et al.
Publicado: (2022)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

Surprisal Analysis of Glioblastoma Multiform (GBM) MicroRNA Dynamics Unveils Tumor Specific Phenotype
por: Zadran, Sohila, et al.
Publicado: (2014)

The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme
por: Lai, Rose, et al.
Publicado: (2010)

Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
por: Gebhardt, Brian J, et al.
Publicado: (2014)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
por: Lee, Chooi Yeng, et al.
Publicado: (2016)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

The effect of silver nanoparticles (AgNPs) on proliferation and apoptosis of in ovo cultured glioblastoma multiforme (GBM) cells
por: Urbańska, Kaja, et al.
Publicado: (2015)

Prognostic utility of lncRNAs (LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme (GBM)
por: Amer, Rehab G., et al.
Publicado: (2022)

OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
por: Towner, Rheal A., et al.
Publicado: (2018)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

HGG-06. Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma without H3 K27M or BRAF Mutations: A Report from the Children's Oncology Group ACNS1721 Study
por: Karajannis, Matthias, et al.
Publicado: (2022)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
por: Heynckes, Sabrina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_59hgbkp6ni98s9blaig05brte1